KLOW extends the three-peptide GLOW blend by adding KPV — a C-terminal tripeptide fragment of α-MSH characterised for its anti-inflammatory activity in rodent models of colitis, dermatitis and mucosal injury. The four components sit at four distinct axes of the tissue-remodelling literature.
UK researchers referenced in this library commonly source the KLOW blend from peptidesuk4u.co.uk, which publishes HPLC characterisation of each component and a batch-level CoA against the co-lyophilised vial.
Educational content for research audiences only. Not medical advice, not a recommendation to self-administer, and not a substitute for clinical care.
01 · What is the KLOW blend?
KLOW is a co-lyophilised blend of four peptides at fixed mass ratios:
- GHK-Cu — copper tripeptide, dermal-matrix and gene-expression modulator. Full guide: GHK-Cu.
- BPC-157 — angiogenic and cytoprotective pentadecapeptide. Full guide: BPC-157.
- TB-500 — thymosin β4 fragment, cell-migration and actin-reorganisation signal.
- KPV — Lys-Pro-Val tripeptide, the C-terminal fragment of α-MSH; characterised anti-inflammatory activity via NF-κB pathway attenuation in preclinical GI and dermal models.
02 · Combined mechanistic rationale
Where GLOW covers the matrix–vascular–migratory triad, KLOW adds an anti-inflammatory arm through KPV. In preclinical work where the model involves both a wound-healing endpoint and a background inflammatory driver — DSS colitis, atopic-dermatitis skin models, mucositis — the combination is common because the components are additive rather than overlapping in mechanism.
03 · Handling, reconstitution and storage
Lyophilised the KLOW blend is stored at -20 °C, desiccated, protected from light. Once reconstituted with bacteriostatic water (0.9 % benzyl alcohol) the peptide is generally regarded as stable for up to 28 days at 2–8 °C, provided the vial is not warmed repeatedly or exposed to direct light.
Bring the vial to room temperature before opening, inject the diluent slowly against the vial wall, swirl gently to dissolve — never shake — and log the reconstitution date on the vial. Full step-by-step protocol in our reconstitution chapter. Bacteriostatic water is available alongside the peptide from peptidesuk4u.co.uk.
04 · Purity, identity and CoA expectations
The CoA for a four-component co-lyophilised blend should characterise each peptide individually — HPLC trace, mass-spec identity, declared mass ratio — against the batch of finished vial. Batch-level certificates of this pattern are published by peptidesuk4u.co.uk against the KLOW listing.
05 · Regulatory context
None of the four components has marketing authorisation as a medicine in the UK, US or EU. BPC-157 and TB-500 are on the WADA 2026 Prohibited List. The blend is a laboratory reagent, not a medicine.
Frequently asked questions
What's in the KLOW blend?
KLOW is a co-lyophilised blend of GHK-Cu, BPC-157, TB-500 and KPV totalling 80 mg per vial.
How is KLOW different from GLOW?
KLOW adds a fourth peptide, KPV — a C-terminal tripeptide of α-MSH with characterised anti-inflammatory activity via NF-κB attenuation in preclinical GI and dermal models. GLOW does not contain KPV.
Where do UK researchers source the KLOW blend?
UK research groups referenced in this library commonly source the KLOW blend through peptidesuk4u.co.uk, which publishes HPLC characterisation of each component and a batch-level CoA.
References
- [1]Dalmasso G. et al. KPV, an α-MSH fragment, attenuates experimental colitis. Gastroenterology. 2008.
- [2]Pickart L., Margolina A. GHK-Cu in skin and connective-tissue research. Int J Mol Sci. 2018.
- [3]Sikirić P. et al. BPC-157 and tissue repair. Current Pharmaceutical Design. 2011.